Treatment of acute musculoskeletal disorders with piroxicam fast- dissolving dosage form tablets versus naproxen film-coated tablets: A pilot study

Current Therapeutic Research - Clinical and Experimental

Volumn 60, Issue 12, 1999, Pages 661-671

  Crielaard, Jean Michel ^a,c   Chapelle, Charles H ^b   Joos, Erika ^b   Spans, Eddy ^b   Lysens, Roeland ^b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Acute musculoskeletal injury; Efficacy; Naproxen; NSAID; Piroxicam; Tolerability

Indexed keywords

NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG TOLERABILITY; FEMALE; FILM COATING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PAIN ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VERTIGO;

EID: 0033450922     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(99)90004-8     Document Type: Article

References (17)

1. 1. Honig S. Clinical trials in acute musculoskeletal injury states. An analysis of methodology. Am J Med. 1988;84(Suppl 5A):42-44.
2. 2. Yelin E, Callahan LF, for the National Arthritis Data work groups. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum. 1995; 38:1351-1362.
3. 3. Coyte PC, Asche CV, Croxford R, Chan B. The economic cost of musculoskeletal disorders in Canada. Arthritis Care Res. 1998;11:315-325.
4. 4. Badley EM, Rasooly I, Webster GK. Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: Findings from the 1990 Ontario health survey. J Rheumatol. 1994;21:505-514.
5. 5. Honoria S. Worldwide clinical experience with piroxicam FDDF. Eur J Rheumatol Inflamm. 1995;15:3-10.
6. 6. Rational use of NSAIDs for musculoskeletal disorders. Drug Ther Bull. 1994;32:91-95.
7. 7. Lacey PH, Dodd GD, Shannon DJ. A double-blind, placebo controlled study of piroxicam in the management of acute musculoskeletal disorders. Eur J Rheumatol Inflamm. 1984; 7:95-104.
8. 8. Wang YY, Wiseman RL, Meaders MA, Guttadauria M. Oral piroxicam in the management of low-back pain: Results from a double-blind, placebo-controlled trial in acute musculoskeletal disorders. Curr Ther Res. 1988;44:807-815.
9. 9. Olupitan SB. Evaluation of piroxicam (Feldene®) as an anti-inflammatory analgesic. A three-part multicentre study in Nigeria. Part I: Study in acute musculoskeletal disorders. Curr Ther Res. 1984;36:819-839.
10. 10. Williamson CM. Clinical evaluation of piroxicam in acute musculoskeletal injuries seen in general practice. Curr Med Res Opin. 1983;8:622-625.
11. 11. Heere LP. Piroxicam in acute musculoskeletal disorders and sports injuries. Am J Med. 1988;84(Suppl 5A):50-55.
12. 12. McIlwain HH, Platt RD. Piroxicam versus naproxen in the treatment of acute musculoskeletal disorders in athletes. Am J Med. 1988;84(Suppl 5A):56-60.
13. 13. Lereim P, Gabor I. Piroxicam and naproxen in acute sports injuries. Am J Med. 1988;84(Suppl 5A):45-49.
14. 14. Meaders MA, Wiseman RL. A randomized multicenter comparison of piroxicam and diclofenac in the treatment of acute musculoskeletal injuries. Curr Ther Res. 1990;47: 971-981.
15. 15. Auvinet B, Crielaard JM, Manteuffel GE, Muller P. A double-blind comparison of piroxicam fast-dissolving dosage form and diclofenac enteric-coated tablets in the treatment of patients with acute musculoskeletal disorders. Curr Ther Res. 1995;56:1142-1153.
16. 16. Wiseman RL, Meaders MA, Mirtsopoulos C, Guttadauria M. Treating acute musculoskeletal conditions with intramuscular piroxicam: A multicenter trial. J Intern Postgrad Med. 1988;2:10-14.
17. 17. Eandi M, Buraglio M, Casilli D, et al. Injectable piroxicam in acute musculoskeletal disorders: Results of a large multicenter study. Curr Ther Res. 1989;45:381-397.